Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Gyre Therapeutics Inc (GYRE)

Gyre Therapeutics Inc (GYRE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 692,634
  • Shares Outstanding, K 96,333
  • Annual Sales, $ 105,760 K
  • Annual Income, $ 12,090 K
  • EBIT $ 12 M
  • EBITDA $ 14 M
  • 60-Month Beta 1.96
  • Price/Sales 6.54
  • Price/Cash Flow 36.35
  • Price/Book 5.03

Options Overview Details

View History
  • Implied Volatility 632.83% (+172.45%)
  • Historical Volatility 39.45%
  • IV Percentile 98%
  • IV Rank 94.92%
  • IV High 661.68% on 11/19/25
  • IV Low 93.22% on 07/28/25
  • Expected Move (DTE 21) 2.26 (30.97%)
  • Put/Call Vol Ratio 10.00
  • Today's Volume 11
  • Volume Avg (30-Day) 17
  • Put/Call OI Ratio 1.36
  • Today's Open Interest 347
  • Open Int (30-Day) 298
  • Expected Range 5.04 to 9.56

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 0.08
  • Number of Estimates 2
  • High Estimate 0.10
  • Low Estimate 0.06
  • Prior Year 0.01
  • Growth Rate Est. (year over year) +700.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.92 +6.26%
on 12/19/25
8.50 -13.53%
on 12/10/25
-0.50 (-6.37%)
since 11/26/25
3-Month
6.92 +6.26%
on 12/19/25
9.42 -21.97%
on 10/16/25
+0.19 (+2.65%)
since 09/26/25
52-Week
6.11 +20.29%
on 04/09/25
14.42 -49.04%
on 12/27/24
-5.78 (-44.02%)
since 12/26/24

Most Recent Stories

More News
Gyre Therapeutics Reports Third Quarter 2025 and Year-to-Date Financial Results and Provides Business Update

Net income of $5.9 million and $11.2 million for the three and nine months ended September 30, 2025, respectively  Full-year revenue guidance revised to $115-118 million (from $118 - $128...

GYRE : 7.26 (+0.90%)
Gyre Therapeutics Announces Completion of Patient Enrollment in Phase 3 Clinical Trial of Pirfenidone Capsules for the Treatment of Pneumoconiosis

SAN DIEGO, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ systems...

GYRE : 7.26 (+0.90%)
Gyre Therapeutics to Present Results from Positive Phase 3 Clinical Trial Evaluating Hydronidone for the Treatment of Liver Fibrosis in Chronic Hepatitis B at AASLD—The Liver Meeting® 2025

SAN DIEGO, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across...

GYRE : 7.26 (+0.90%)
Gyre Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

SAN DIEGO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies...

GYRE : 7.26 (+0.90%)
Gyre Therapeutics Announces the Appointment of Dan Weng, M.D., to Board of Directors

SAN DIEGO, Aug. 22, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across...

GYRE : 7.26 (+0.90%)
Gyre Therapeutics Reports Second Quarter 2025 and Year-to-Date Financial Results and Provides Business and Leadership Update

  Net income of $1.6 million and $5.3 million for the three and six months ended June 30, 2025, respectively; reaffirms full-year revenue guidance of $118-128 million Ping Zhang,...

GYRE : 7.26 (+0.90%)
Gyre Therapeutics Announces First Dosing in Phase 1 Trial of F230 for Pulmonary Arterial Hypertension in China

GYRE : 7.26 (+0.90%)
Gyre Therapeutics Announces Closing of its Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

GYRE : 7.26 (+0.90%)
Gyre Therapeutics Announces Pricing of $20.0 Million Public Offering of Common Stock

GYRE : 7.26 (+0.90%)
Gyre Therapeutics Announces Proposed Underwritten Public Offering of Common Stock

GYRE : 7.26 (+0.90%)

Business Summary

Gyre Therapeutics Inc. is a biotechnology company. It focused on organ fibrosis and inflammatory diseases. The company's product pipeline primarily includes F573, F528 and F230. Gyre Therapeutics Inc., formerly known as Catalyst Biosciences Inc., is based in United States.

See More

Key Turning Points

3rd Resistance Point 7.44
2nd Resistance Point 7.33
1st Resistance Point 7.26
Last Price 7.26
1st Support Level 7.09
2nd Support Level 6.98
3rd Support Level 6.91

See More

52-Week High 14.42
Fibonacci 61.8% 11.25
Fibonacci 50% 10.27
Fibonacci 38.2% 9.29
Last Price 7.26
52-Week Low 6.11

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar